Who Prioritizes Innovation? R&D Spending Compared for ACADIA Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.

Pharma Giants' R&D Race: ACADIA vs. Iovance

__timestampACADIA Pharmaceuticals Inc.Iovance Biotherapeutics, Inc.
Wednesday, January 1, 2014606020002704597
Thursday, January 1, 20157386900015470000
Friday, January 1, 20169928400028037000
Sunday, January 1, 201714918900071615000
Monday, January 1, 201818716300099828000
Tuesday, January 1, 2019240385000166023000
Wednesday, January 1, 2020319130000201727000
Friday, January 1, 2021239415000259039000
Saturday, January 1, 2022361575000294781000
Sunday, January 1, 2023351619000344077000
Loading chart...

Unveiling the hidden dimensions of data

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving world of pharmaceuticals, innovation is key to staying ahead. Over the past decade, ACADIA Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc. have demonstrated their commitment to research and development (R&D) with significant investments. From 2014 to 2023, ACADIA's R&D spending surged by nearly 480%, peaking in 2022. Meanwhile, Iovance's R&D expenses skyrocketed by an astonishing 12,600% during the same period, reflecting their aggressive pursuit of innovation.

In 2023, both companies reached a near parity in R&D spending, with ACADIA investing slightly more than $350 million and Iovance close behind. This trend highlights a growing emphasis on innovation as both companies strive to develop groundbreaking therapies. As the pharmaceutical landscape continues to shift, these investments underscore the critical role of R&D in driving future growth and success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025